Evobrutinib
- Generic Name
- Evobrutinib
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27N5O2
- CAS Number
- 1415823-73-2
- Unique Ingredient Identifier
- ZA45457L1K
- Background
Evobrutinib is under investigation in clinical trial NCT03934502 (Effect of Meal Composition and Timing on Evobrutinib Bioavailability).
Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 6
- Registration Number
- NCT03725072
- Locations
- π³π±
PRA Health Sciences, Groningen, Netherlands
Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2019-05-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 31
- Registration Number
- NCT03436394
- Locations
- π©πͺ
Please Contact the Merck KGaA Communication Center, Darmstadt, Germany
A Phase II Study of M2951 in SLE
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2021-04-12
- Target Recruit Count
- 469
- Registration Number
- NCT02975336
- Locations
- πΊπΈ
Advanced Research Center, Inc., Anaheim, California, United States
πΊπΈUniversity of Southern California, Los Angeles, California, United States
πΊπΈPinnacle Research Group LLC, Anniston, Alabama, United States
A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2016-11-29
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 267
- Registration Number
- NCT02975349
- Locations
- πΊπ¦
Research Site, Zaporizhzhia, Ukraine
π§π¬Research Site 1, Pleven, Bulgaria
π§π¬Research Site 2, Pleven, Bulgaria
Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2018-07-17
- Target Recruit Count
- 65
- Registration Number
- NCT02784106
- Locations
- π©πͺ
Merck KGaA Communication Center, Darmstadt, Germany
πΊπΈU.S. Medical Information, Billerica, Massachusetts, United States
MSC2364447C Phase 1b in Systemic Lupus Erythematosus
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2017-10-09
- Target Recruit Count
- 24
- Registration Number
- NCT02537028
- Locations
- π§π¬
Research site, Sofia, Bulgaria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.